Aldeyra Therapeutics, Inc.
General ticker "ALDX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $280.8M (TTM average)
Aldeyra Therapeutics, Inc. follows the US Stock Market performance with the rate: 33.9%.
Estimated limits based on current volatility of 4.0%: low 4.84$, high 5.24$
Factors to consider:
- Total employees count: 9 (-10.0%) as of 2024
- Top business risk factors: Regulatory and compliance, Quarterly fluctuations, Liquidity and credit risks, Acquisition/divestiture risks, Cybersecurity threats
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [3.29$, 8.04$]
- 2025-12-31 to 2026-12-31 estimated range: [2.86$, 7.17$]
Financial Metrics affecting the ALDX estimates:
- Positive: with PPE of -5.2 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -14.81 <= 0.33
- Positive: Shareholder equity ratio, % of 67.88 > 63.39
- Negative: negative Industry operating cash flow (median)
- Positive: Inventory ratio change, % of -100 <= -0.75
Short-term ALDX quotes
Long-term ALDX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $62.68MM | $42.79MM | $60.12MM |
| Operating Income | $-62.68MM | $-42.79MM | $-60.12MM |
| Non-Operating Income | $0.66MM | $5.25MM | $4.27MM |
| Interest Expense | $1.69MM | $2.07MM | $1.93MM |
| R&D Expense | $47.31MM | $29.46MM | $48.22MM |
| Income(Loss) | $-62.02MM | $-37.54MM | $-55.85MM |
| Profit(Loss)* | $-62.02MM | $-37.54MM | $-55.85MM |
| Stockholders Equity | $151.01MM | $119.80MM | $71.00MM |
| Assets | $181.29MM | $148.33MM | $104.61MM |
| Operating Cash Flow | $-56.64MM | $-30.33MM | $-43.21MM |
| Capital expenditure | $0.02MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $-29.95MM | $30.00MM | $-44.92MM |
| Financing Cash Flow | $1.22MM | $-1.27MM | $-0.17MM |
| Earnings Per Share** | $-1.06 | $-0.64 | $-0.94 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.